chronic pelvic pain syndrome
Conditions
Interventions
dual-targeted magnetic stimulation group:Repetitive transcranial magnetic stimulation combined with repetitive trans sacral 3 nerve magnetic stimulation
peripheral magnetic stimulation group:Sham transcranial magnetic stimulation combined with repetitive trans sacral 3 nerve magnetic stimulation
sham stimulation group:Use a coil that does not produce a magnetic field, only emits sound, and perform sham stimulation first through the scalp and then through the sacral 3 area.
Sponsors
Chengdu Anorectal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Compliance with the European Association of Urology (EAU) guidelines for chronic pelvic pain (2022 edition) CPPS diagnostic criteria. (2) Age: 18-60 years old. (3) Definite diagnosis of anxiety or depression. (4) Gynaecological examination and auxiliary examination did not reveal clear pathological changes. (5) Obtained informed consent and entered the study voluntarily. (6) Not receiving any treatment modality within 3 months prior to the visit. (7) Patients gave informed consent and voluntarily participated in this study.
Exclusion criteria
Exclusion criteria: (1) Patients in the acute phase of systemic and intracranial haemorrhagic diseases. (2) Those with combined cardiovascular, cerebrovascular, hepatic, renal, respiratory and haematopoietic systems and other serious primary diseases, malignant tumours and/or other progressive underlying diseases. (3) Patients with metal heart membranes, pacemakers, intracranial metal implants, lumbosacral metal implants and implantable electronic devices. (4) Those with intracranial or lumbosacral infections. (5) Patients with unstable vital characteristics. (6) Patients with adverse reactions to magnetic therapy. (7) Patients with abnormal autonomic reflexes. (8) Combined cognitive dysfunction can not cooperate. (9) Pregnant and lactating women. (10) Patients with previous history of diabetes mellitus, alcoholism and toxicity and any other diseases that cause peripheral nerve damage.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pelvic Pain Assessment Scale;Phenotype classification system (UPOINTS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression Anxiety and Stress Scale;SF-36 Quality of Life Scale; | — |
Countries
China
Contacts
Public ContactXiangdong Yang
Chengdu Anorectal Hospital
Outcome results
None listed